(MedPage Today) — In an analysis of Medicare’s top-selling brand-name oncology drugs, researchers found that while the vast majority provided high added therapeutic benefit, 10 were classified as providing low or no added benefit. In 2022, Medicare… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/114981 Author : Publish date : 2025-04-04 21:02:00 Copyright for syndicated content belongs to the […]
The post Medicare Spends Billions on Oncology Drugs Offering Little Added Benefit first appeared on News Health.
Author : News Health
Publish date : 2025-04-04 21:02:00
Copyright for syndicated content belongs to the linked Source.